Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia.
about
Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemiaColony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemiaTimed sequential chemotherapy with concomitant granulocyte colony-stimulating factor for high-risk acute myelogenous leukemia: a single arm clinical trialWIPI-dependent autophagy during neutrophil differentiation of NB4 acute promyelocytic leukemia cells.Efficacy of colony-stimulating factors in acute leukemia.PU.1 is linking the glycolytic enzyme HK3 in neutrophil differentiation and survival of APL cells.Inhibition of GATE-16 attenuates ATRA-induced neutrophil differentiation of APL cells and interferes with autophagosome formation.Mesenchymal stem cell therapy for acute radiation syndrome: innovative medical approaches in military medicineProspective Randomization Trial of G-CSF-Primed Induction Regimen versus Standard Regimen in Patients with AML.Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value.Low DICER1 expression is associated with attenuated neutrophil differentiation and autophagy of NB4 APL cells.Including historical data in the analysis of clinical trials: Is it worth the effort?Role of cytokines in the treatment of acute leukemias: a review.BIRC6 (APOLLON) is down-regulated in acute myeloid leukemia and its knockdown attenuates neutrophil differentiation.Prognostic impact of white blood cell count in intermediate risk acute myeloid leukemia: relevance of mutated NPM1 and FLT3-ITD.The tumor suppressor gene DAPK2 is induced by the myeloid transcription factors PU.1 and C/EBPα during granulocytic differentiation but repressed by PML-RARα in APL.Expression of a passenger miR-9* predicts favorable outcome in adults with acute myeloid leukemia less than 60 years of age.The autophagy scaffold protein ALFY is critical for the granulocytic differentiation of AML cells.Proliferative activity of leukaemic blasts and cytosine arabinoside pharmacodynamics are associated with cytogenetically defined prognostic subgroups in acute myeloid leukaemia.Timed-sequential chemotherapy with concomitant granulocyte colony-stimulating factor for newly diagnosed de novo acute myelogenous leukemia.SEIFEM 2017: from real life to an agreement on the use of granulocyte transfusions and colony-stimulating factors for prophylaxis and treatment of infectious complications in patients with hematologic malignant disorders.Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia.Mathematical modeling of the impact of cytokine response of acute myeloid leukemia cells on patient prognosis.
P2860
Q24202698-A4A59F5A-5DBD-4E17-89D1-2D455E84F0C0Q24234458-22751770-8DA3-4612-8EA8-15A850A7B1E8Q24792014-15F6479D-66EA-4704-B674-DB3D1840724BQ34007677-8906C4A8-2ECB-40F9-90DD-B5410B5471DFQ34150820-AF44AEB2-A294-48BB-AA06-92B08C54D5A1Q34267963-E26DDA43-11AE-458B-B584-6DD70AD1EAC4Q34478666-EB27DADB-081E-4A7B-B36E-848A3D3D8C74Q35122122-6482AC1A-A0E0-4F4F-BF03-2597DA5772C9Q35546219-957DDE1C-3327-4CB5-87F0-31D16FC9750FQ35794435-8C7BC782-9DF4-4173-B349-71341E5BAD51Q35970498-78A0ADDF-B181-4074-AFCA-F83732AB4C1DQ36315895-CB7F41D0-F8DE-4299-B0F3-CC6960DD6C4AQ36405044-D1CC2E1B-3F32-46BD-AC02-2F20A3C32365Q36444491-D30B63E6-FF43-4C0C-9B92-5AB843AA844EQ38289289-08EF8750-B847-4249-AB2B-8888B47334C0Q39095775-A4DC2584-00FC-41B8-BC9E-B406C43AD482Q41225296-E59625F3-98A5-4666-A65E-4E306DA21F0FQ42374936-3F152228-1E2E-4BC4-8AEB-A07490A6ACEAQ43665960-680259EE-4091-4E07-94DD-6885CA192A45Q44452168-33EA555A-CBEE-4534-848B-813C40B7B4E9Q47235713-5EED8E97-C530-41CE-B72C-9A7C932EEEC6Q47978464-D32191B4-F0D9-4AEF-B4E3-714AA1B6CFFAQ49402805-0A1A2C17-C319-40DC-92F6-D286F43520A7
P2860
Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Value of different modalities ...... apy of acute myeloid leukemia.
@en
type
label
Value of different modalities ...... apy of acute myeloid leukemia.
@en
prefLabel
Value of different modalities ...... apy of acute myeloid leukemia.
@en
P2093
P1476
Value of different modalities ...... apy of acute myeloid leukemia.
@en
P2093
A Gratwohl
A Hagenbeek
B Löwenberg
E Vellenga
G E Verhoef
G J Ossenkoppele
H C Schouten
J J Wielenga
J van der Lelie
P304
P356
10.1200/JCO.1997.15.12.3496
P407
P577
1997-12-01T00:00:00Z